S. O'Sullivan, M. Farrant, C. M. Ogilvie, A. Gunn, S. Milsom
{"title":"多巴胺激动剂治疗催乳素瘤妇女妊娠和产后结局的观察性研究","authors":"S. O'Sullivan, M. Farrant, C. M. Ogilvie, A. Gunn, S. Milsom","doi":"10.1111/ajo.13070","DOIUrl":null,"url":null,"abstract":"In women with prolactinoma medical treatment with dopamine agonists (DA) can restore fertility. A number of studies have established the safety of DA during pregnancy and the impact of pregnancy and lactation on remission of prolactinoma. However, the total number of reported cases remains modest and further evidence is needed.","PeriodicalId":8599,"journal":{"name":"Australian and New Zealand Journal of Obstetrics and Gynaecology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"An observational study of pregnancy and post‐partum outcomes in women with prolactinoma treated with dopamine agonists\",\"authors\":\"S. O'Sullivan, M. Farrant, C. M. Ogilvie, A. Gunn, S. Milsom\",\"doi\":\"10.1111/ajo.13070\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In women with prolactinoma medical treatment with dopamine agonists (DA) can restore fertility. A number of studies have established the safety of DA during pregnancy and the impact of pregnancy and lactation on remission of prolactinoma. However, the total number of reported cases remains modest and further evidence is needed.\",\"PeriodicalId\":8599,\"journal\":{\"name\":\"Australian and New Zealand Journal of Obstetrics and Gynaecology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australian and New Zealand Journal of Obstetrics and Gynaecology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/ajo.13070\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian and New Zealand Journal of Obstetrics and Gynaecology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/ajo.13070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
An observational study of pregnancy and post‐partum outcomes in women with prolactinoma treated with dopamine agonists
In women with prolactinoma medical treatment with dopamine agonists (DA) can restore fertility. A number of studies have established the safety of DA during pregnancy and the impact of pregnancy and lactation on remission of prolactinoma. However, the total number of reported cases remains modest and further evidence is needed.